Electric fields and pill combo takes on deadly brain tumor

NCT ID NCT04221503

Ongoing Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of the drug niraparib and a device that delivers electric fields (Tumor-Treating Fields) in 30 people with recurrent glioblastoma, an aggressive brain cancer. The goal is to see if the combo can control the tumor, shrink it, or keep it stable. Participants must have had prior radiation and have measurable disease on MRI.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: niraparib (a PARP inhibitor) and Tumor-Treating Fields (electric fields delivered via a device)
What this could lead to: If it works, this could offer a new way to control recurrent glioblastoma, potentially slowing tumor growth and extending life.
What could go wrong: This is a small, early-phase trial with only 30 people, so results may not apply to everyone. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GBM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GBM GLIOBLASTOMA RECURRENT GLIOBLASTOMA

Contacts and locations

Locations

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.